News / Events

Abeona Therapeutics Cleared to Initiate Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

Abeona Therapeutics Reports Third Quarter 2019 Financial Results and Business Updates

Third Quarter 2019 Earnings Call

Nov 13, 2019 • 10:00am EST

27th European Society of Gene and Cell Therapy (ESGCT) Congress

Oct 22 – Oct 25, 2019